Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen Grimes

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Biomedical Instrumentation & Technology|September 28, 2018
A Rational Approach to Efficient Equipment Maintenance, Part 2: A Comprehensive AEM ProgramMalcolm Ridgway, Matthew F Baretich, Matthew Clark, et al.
Vaccine|February 7, 2022
MAS-1, a novel water-in-oil adjuvant/delivery system, with reduced seasonal influenza vaccine hemagglutinin dose may enhance potency, durability and cross-reactivity of antibody responses in the elderlyGeoffrey J Gorse, Stephen Grimes, Helen Buck, et al.
Vaccine|February 7, 2022
A phase 1 dose-sparing, randomized clinical trial of seasonal trivalent inactivated influenza vaccine combined with MAS-1, a novel water-in-oil adjuvant/delivery systemGeoffrey J Gorse, Stephen Grimes, Helen Buck, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Biomedical Instrumentation & Technology|September 28, 2018
A Rational Approach to Efficient Equipment Maintenance, Part 2: A Comprehensive AEM ProgramMalcolm Ridgway, Matthew F Baretich, Matthew Clark, et al.
Vaccine|February 7, 2022
MAS-1, a novel water-in-oil adjuvant/delivery system, with reduced seasonal influenza vaccine hemagglutinin dose may enhance potency, durability and cross-reactivity of antibody responses in the elderlyGeoffrey J Gorse, Stephen Grimes, Helen Buck, et al.
Vaccine|February 7, 2022
A phase 1 dose-sparing, randomized clinical trial of seasonal trivalent inactivated influenza vaccine combined with MAS-1, a novel water-in-oil adjuvant/delivery systemGeoffrey J Gorse, Stephen Grimes, Helen Buck, et al.
Pageof 2